Idoxuridine

Idoxuridine

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a601062
Pregnancy category	US: C (Risk not ruled out) B1 (topical), B3 (ophthalmologic) [AU]
Routes of administration	topically
ATC code	D06BB01 (WHO) J05AB02 (WHO), S01AD01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)
Identifiers
IUPAC name 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodo-1,2,3,4-tetrahydropyrimidine-2,4-dione
Synonyms	Iododeoxyuridine; IUdR
CAS Number	54-42-2 Y
PubChem CID	5905
DrugBank	DB00249 Y
ChemSpider	10481938 Y
UNII	LGP81V5245
KEGG	D00342 Y
ChEMBL	CHEMBL788 N
NIAID ChemDB	001857
ECHA InfoCard	100.000.189
Chemical and physical data
Formula	C9H11IN2O5
Molar mass	354.099 g/mol
3D model (Jmol)	Interactive image
SMILES I\C1=C\N(C(=O)NC1=O)C2C[C@H](O)[C@@H](CO)O2
InChI InChI=1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7?/m0/s1 Y Key:XQFRJNBWHJMXHO-GFCOJPQKSA-N Y
NY (what is this?)

Idoxuridine is an anti-herpesvirus antiviral drug.

It is a nucleoside analogue, a modified form of deoxyuridine, similar enough to be incorporated into viral DNA replication, but the iodine atom added to the uracil component blocks base pairing. It is used only topically due to cardiotoxicity. It was synthesized by William Prusoff in the late 1950s. Initially developed as an anticancer drug, idoxuridine became the first antiviral agent in 1962.

Idoxuridine is mainly used topically to treat herpes simplex keratitis. Epithelial lesions, especially initial attacks presenting with a dendritic ulcer, are most responsive to therapy, while infection with stromal involvement are less responsive. Idoxuridine is ineffective against herpes simplex virus type 2 and varicella-zoster.

Common side effects of the eye drops include irritation, blurred vision and photophobia.Corneal clouding and damage of the corneal epithelium may also occur.

Idoxuridine is available as either a 0.5% ophthalmic ointment or as a 0.1% ophthalmic solution. The dosage of the ointment is every 4 hours during day and once before bedtime. The dosage of the solution is 1 drop in the conjunctival sac hourly during the day and every 2 hours during the night until definitive improvement, then 1 drop every 2 hours during the day and every 4 hours during the night. Therapy is continued for 3–4 days after healing is complete, as demonstrated by fluorescein staining.